Clene's ALS drug and uniQure's Huntington's disease gene therapy hope for a smooth road to accelerated approval despite the pathway's difficult history in neurodegenerative disease. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
